In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols Babesia test for samples received on April 20, 2020 at the Charlotte, Dallas, Phoenix, St. Louis and Tampa laboratories. Be watching for details on an upcoming webinar that will provide you with an overview of implementing this testing.
Check out the Communication page for the complete details by clicking the link: Communications
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...